Status:
COMPLETED
A Genome-Wide Scan For Quantitative Trait Loci of Serum Bilirubin - A Framingham Study
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Genetics
Eligibility:
All Genders
Brief Summary
Studies have shown that there is a significant association between serum bilirubin concentrations and risk of coronary artery disease (CAD). So far, no linkage analysis in humans between serum bilirub...
Detailed Description
Many studies showed that there is a significant relationship between serum bilirubin levels and risk of coronary artery disease (CAD). We carried out a genome-wide scan for quantitative trait loci of ...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- The study population will include the members of the 330 Framingham Study families and 1888 random individuals.
- The Original Cohort will also be included.
Exclusion
Key Trial Info
Start Date :
October 26 2001
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 23 2013
Estimated Enrollment :
1888 Patients enrolled
Trial Details
Trial ID
NCT00340509
Start Date
October 26 2001
End Date
July 23 2013
Last Update
December 16 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Heart, Lung and Blood Institute (NHLBI), 9000 Rockville Pike
Bethesda, Maryland, United States, 20892